Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma

被引：21

作者：

Nakano, M. ^{[1
]}

Kuromatsu, R. ^{[1
]}

Niizeki, T. ^{[1
]}

Okamura, S. ^{[1
]}

Iwamoto, H. ^{[1
]}

Shimose, S. ^{[1
]}

Shirono, T. ^{[1
]}

Noda, Y. ^{[1
]}

Kamachi, N. ^{[1
]}

Koga, H. ^{[1
]}

Torimura, T. ^{[1
]}

机构：

[1] Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

来源：

ESMO OPEN | 2021年 / 6卷 / 01期

关键词：

advanced hepatocellular carcinoma; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; prognosis; LYMPHOCYTE RATIO; SURVIVAL; CRITERIA; NEUTROPHIL; SORAFENIB; DIAGNOSIS; CTCAE;

D O I：

10.1016/j.esmoop.2020.100020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The immunological inflammatory biomarkers for advanced hepatocellular carcinoma are unclear. We aimed to investigate the association of immunity and inflammatory status with treatment outcomes in patients with advanced hepatocellular carcinoma who received molecular-targeted agents as primary treatment. Patients and methods: We enrolled 728 consecutive patients with advanced hepatocellular carcinoma who received sorafenib (n = 554) or lenvatinib (n = 174) as primary treatment in Japan between May 2009 and June 2020. Changes in the neutrophil-to-lymphocyte ratio before and 1 month after treatment and their impact on survival were evaluated. The cut-off values of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for predicting overall and progression-free survival were calculated using receiver operating characteristic curves. Results: The neutrophil-to-lymphocyte ratio, but not the platelet-to-lymphocyte ratio, was an independent prognostic factor. Patients with decreased neutrophil-to-lymphocyte ratio survived significantly longer than patients with increased neutrophil-to-lymphocyte ratio (median overall survival: 14.7 versus 10.4 months, P = 0.0110). Among patients with a low pre-treatment neutrophil-to-lymphocyte ratio, the overall survival did not differ significantly between those with decreased and those with increased neutrophil-to-lymphocyte ratio after 1 month (median: 19.0 versus 14.8 months, P = 0.1498). However, among patients with high pre-treatment neutrophil-to-lymphocyte ratio, those whose neutrophil-to-lymphocyte ratio decreased after 1 month showed significantly longer survival than those whose neutrophil-to-lymphocyte ratio increased (median: 12.7 versus 5.5 months, P < 0.0001). The therapeutic effect was not correlated with pre-treatment neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio. Conclusions: The neutrophil-to-lymphocyte ratio is a prognostic factor, along with liver function and tumor markers, in patients with advanced hepatocellular carcinoma who received molecular-targeted agents as primary treatment. Thus, the neutrophil-to-lymphocyte ratio could be a prognostic biomarker for advanced hepatocellular carcinoma primarily treated with immunotherapy.

引用

页数：8

共 41 条

[11] Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects [J].